



4050.001100.ST25
SEQUENCE LISTING

<110> Smythe , Mark Leslie
Meutermans, Wim Denis Franss

<120> Auxiliary for Amide Bond Formation

<130> 4050.001100

<140> 09/787,840

<141> 2001-07-06

<150> PCT/AU99/00812

<151> 1999-09-24

<150> AU PP6165

<151> 1998-09-25

<160> 43

<170> PatentIn version 3.2

<210> 1

<211> 4

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC LINEAR PEPTIDE

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> Xaa = HS-(CH₂)₂-Tyr

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> Xaa = Gly-OH

<400> 1

Xaa Arg Phe Xaa

1

<210> 2

<211> 4

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC LINEAR PEPTIDE

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> Xaa = butyl-Tyr substituted

<220>

<221> MISC_FEATURE

<222> (2)..(2)
<223> Xaa = 2,2,5,7,8-pentamethylchroman-6-sulfonyl-Arg

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa = Gly WANG resin

<400> 2

Xaa Xaa Phe Xaa
1

<210> 3
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(5-nitro-2-mercaptobenzyl)-Tyr

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa = Gly-OH

<400> 3

Xaa Arg Phe Xaa
1

<210> 4
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = HS-(CH₂)₂-Ala

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa = Ala-OH

<400> 4

Xaa Phe Leu Pro Xaa
1 5

<210> 5
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa = Ala-WANG resin

<400> 5

Ala Phe Leu Pro Xaa
1 5

<210> 6
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = HS-(CH₂)₂-NH-CH(CH₃)-CO-Phe

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa = Ala-OH

<400> 6

Xaa Leu Pro Xaa
1

<210> 7
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(2-hydroxy-5-nitrobenzyl)-Ala

<220>
<221> MISC_FEATURE
<222> (5)..(5)

<223> Xaa = Ala-OH

<400> 7

Xaa Phe Leu Pro Xaa
1 5

<210> 8

<211> 5

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC LINEAR PEPTIDE

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> Xaa a= N-(2-hydroxy-6-nitrobenzyl)-Ala

<220>

<221> MISC_FEATURE

<222> (5)..(5)

<223> Xaa = Ala-OH

<400> 8

Xaa Phe Leu Pro Xaa
1 5

<210> 9

<211> 4

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC LINEAR PEPTIDE

<400> 9

Val Ala Gly Phe
1

<210> 10

<211> 5

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC CYCLIC PEPTIDE

<400> 10

Ala Phe Leu Pro Ala
1 5

<210> 11

<211> 5

4050.001100.ST25

<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(6-nitro-2-hydroxybenzyl)-Phe

<400> 11

Xaa Leu Pro Ala Ala
1 5

<210> 12
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = S-(CH₂)₂-Ala

<400> 12

Xaa Phe Leu Pro Ala
1 5

<210> 13
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = HS-(CH₂)₂-Ala

<400> 13

Xaa Phe Leu Pro Ala
1 5

<210> 14
<211> 8
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = S-(CH₂)₂-NH-CH(CH₃)-CO-Phe

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa = Ala-NH₂

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa = S-(CH₂)₂-NH-CH(CH₃)-CO-Phe

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> Xaa = Ala-OH

<400> 14

Xaa Leu Pro Xaa Xaa Leu Pro Xaa
1 5

<210> 15
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(5-nitro-2-hydroxybenzyl)-Ala

<400> 15

Xaa Phe Leu Pro Ala
1 5

<210> 16
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(6-nitro-2-hydroxybenzyl)-Ala

<400> 16

Xaa Phe Leu Pro Ala
1 5<210> 17
<211> 5
<212> PRT
<213> ARTIFICIAL<220>
<223> SYNTHETIC CYCLIC PEPTIDE<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(6-nitro-2-hydroxybenzyl)-Phe

<400> 17

Xaa Leu Pro Ala Ala
1 5<210> 18
<211> 5
<212> PRT
<213> ARTIFICIAL<220>
<223> SYNTHETIC LINEAR PEPTIDE<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(6-nitro-2-hydroxybenzyl)-Phe

<400> 18

Xaa Leu Pro Ala Ala
1 5<210> 19
<211> 5
<212> PRT
<213> ARTIFICIAL<220>
<223> SYNTHETIC LINEAR PEPTIDE

<400> 19

Ala Phe Leu Pro Ala
1 5<210> 20
<211> 5

<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<400> 20

Phe Leu Pro Ala Ala
1 5

<210> 21
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<400> 21

Tyr Arg Phe Gly
1

<210> 22
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl) substituted Tyr

<400> 22

Xaa Arg Phe Gly
1

<210> 23
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl) substituted Tyr

<400> 23

Xaa Arg Phe Gly

1

<210> 24
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<400> 24

Tyr Arg Phe Gly
1

<210> 25
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<400> 25

Leu Tyr Arg Ala Gly
1 5

<210> 26
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<400> 26

Gly Ala Gly Pro Ala
1 5

<210> 27
<211> 10
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<400> 27

Leu Tyr Arg Ala Gly Gly Ala Gly Pro Ala
1 5 10

<210> 28
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
 <223> SYNTHETIC LINEAR PEPTIDE

<400> 28

Leu Tyr Arg Ala Phe
 1 5

<210> 29
 <211> 5
 <212> PRT
 <213> ARTIFICIAL

<220>
 <223> SYNTHETIC LINEAR PEPTIDE

<400> 29

Ala Ala Arg His Thr
 1 5

<210> 30
 <211> 10
 <212> PRT
 <213> ARTIFICIAL

<220>
 <223> SYNTHETIC LINEAR PEPTIDE

<400> 30

Leu Tyr Arg Ala Phe Ala Ala Arg His Thr
 1 5 10

<210> 31
 <211> 5
 <212> PRT
 <213> ARTIFICIAL

<220>
 <223> SYNTHETIC LINEAR PEPTIDE

<400> 31

Phe Leu Pro Ala Ala
 1 5

<210> 32
 <211> 4
 <212> PRT
 <213> ARTIFICIAL

<220>
 <223> SYNTHETIC CYCLIC PEPTIDE

<400> 32

Phe Phe Phe Phe

1

<210> 33
 <211> 14
 <212> PRT
 <213> ARTIFICIAL

<220>
 <223> SYNTHETIC LINEAR PEPTIDE

<400> 33

Tyr Ala Val Thr Gly Arg Gly Asp Ser Pro Ala Ala Ser Ser
 1 5 10

<210> 34
 <211> 16
 <212> PRT
 <213> ARTIFICIAL

<220>
 <223> SYNTHETIC CYCLIC PEPTIDE

<400> 34

Cys Tyr Ala Val Thr Gly Arg Gly Asp Ser Pro Ala Ala Ser Ser Gly
 1 5 10 15

<210> 35
 <211> 11
 <212> PRT
 <213> ARTIFICIAL

<220>
 <223> SYNTHETIC LINEAR PEPTIDE

<400> 35

Val Ser Ile Leu Glu Thr Lys Ile Tyr Gly Thr
 1 5 10

<210> 36
 <211> 5
 <212> PRT
 <213> ARTIFICIAL

<220>
 <223> SYNTHETIC LINEAR PEPTIDE

<220>
 <221> MISC_FEATURE
 <222> (5)..(5)
 <223> Xaa = Ala-Trityl resin

<400> 36

Ala Phe Leu Pro Xaa
 1 5

<210> 37
 <211> 4
 <212> PRT
 <213> ARTIFICIAL

<220>
 <223> SYNTHETIC LINEAR PEPTIDE

<220>
 <221> MISC_FEATURE
 <222> (4)..(4)
 <223> Xaa = Phe-resin

<400> 37

Val Ala Gly Xaa
 1

<210> 38
 <211> 11
 <212> PRT
 <213> ARTIFICIAL

<220>
 <223> SYNTHETIC LINEAR PEPTIDE

<400> 38

Thr Gly Tyr Ile Lys Thr Glu Leu Ile Ser Val
 1 5 10

<210> 39
 <211> 5
 <212> PRT
 <213> ARTIFICIAL

<220>
 <223> SYNTHETIC LINEAR PEPTIDE

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> Xaa = H-Ala

<220>
 <221> MISC_FEATURE
 <222> (5)..(5)
 <223> Xaa = Ala-OH

<400> 39

Xaa Phe Leu Pro Xaa
 1 5

<210> 40
 <211> 8

<212> PRT
 <213> ARTIFICIAL

<220>
 <223> SYNTHETIC CYCLIC PEPTIDE

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> Xaa = S-(CH₂)₂-NH-CH(CH₃)-CO-Phe

<220>
 <221> MISC_FEATURE
 <222> (4)..(4)
 <223> Xaa = Ala-NH₂

<220>
 <221> MISC_FEATURE
 <222> (5)..(5)
 <223> Xaa = S-(CH₂)₂-NH-CH(CH₃)-CO-Phe

<220>
 <221> MISC_FEATURE
 <222> (8)..(8)
 <223> Xaa = Ala-NH₂

<400> 40

Xaa Leu Pro Xaa Xaa Leu Pro Xaa
 1 5

<210> 41
 <211> 8
 <212> PRT
 <213> ARTIFICIAL

<220>
 <223> SYNTHETIC LINEAR PEPTIDE

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> Xaa = S-(CH₂)₂-NH-CH(CH₃)-CO-Phe

<220>
 <221> MISC_FEATURE
 <222> (4)..(4)
 <223> Xaa = Ala-OH

<220>
 <221> MISC_FEATURE
 <222> (5)..(5)
 <223> Xaa = S-(CH₂)₂-NH-CH(CH₃)-CO-Phe

<220>
 <221> MISC_FEATURE
 <222> (8)..(8)
 <223> Xaa = Ala-OH

<400> 41

Xaa Leu Pro Xaa Xaa Leu Pro Xaa
1 5

<210> 42

<211> 5

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC CYCLIC PEPTIDE

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> xaa = N-(5-nitro-2-hydroxybenzyl)-Ala

<400> 42

Xaa Phe Leu Pro Ala
1 5

<210> 43

<211> 5

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC LINEAR PEPTIDE

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> Xaa = N-(6-nitro-2-hydroxybenzyl)-Ala

<400> 43

Xaa Phe Leu Pro Ala
1 5